iOnctura, a pioneering biopharmaceutical company specializing in innovative cancer treatments, has secured EUR 80 million in Series B financing. This milestone funding round, led by Syncona Limited with participation from the European Innovation Council (EIC) Fund and existing investors, underscores iOnctura’s transformative strides in oncology.
The investment will accelerate the development of iOnctura’s lead candidate, roginolisib, a groundbreaking allosteric modulator of PI3Kδ. Designed to combat immune-mediated resistance prevalent in hard-to-treat cancers like uveal melanoma, roginolisib has shown promising results in Phase Ib trials, demonstrating sustained clinical activity and safety in patients. These achievements build upon earlier successes, including recent clinical data presented at the ESMO Immuno-Oncology Congress 2023, highlighting roginolisib’s potential to enhance antitumoral immunity.
Catherine Pickering, CEO of iOnctura, expressed enthusiasm about the funding’s implications for advancing their precision therapies. “This financing validates iOnctura’s commitment to pioneering treatments that extend patients’ healthspans,” she affirmed. The funds will support expanded trials in diverse cancer indications, including non-small cell lung cancer and primary myelofibrosis, reinforcing iOnctura’s dedication to addressing unmet medical needs.
Roel Bulthuis, Managing Partner at Syncona and iOnctura Board member, emphasized the strategic significance of the investment. “iOnctura’s approach, targeting critical cancer pathways with precision, positions them as leaders in oncology innovation,” he noted. The company’s portfolio also includes cambritaxestat, an autotaxin inhibitor advancing in clinical development to treat highly fibrotic tumors.
Founded with a mission to revolutionize cancer care, iOnctura continues to garner support from specialized institutional investors, affirming its role in shaping the future of oncology treatments.
